page_banner

Products

2,3,5-Triphenyl-2H-tetrazolium chloride Cas:298-96-4 98% Off-white/pale yellow crystalline powder

Short Description:

Catalog Number: XD90154
Cas: 298-96-4
Molecular Formula: C19H15N4·Cl
Molecular Weight: 334.80
Availability: In Stock
Price:  
Prepack: 5g USD10
Bulk Pack: Request Quote

 

 

 

 

 

 

 


Product Detail

Product Tags

Catalog Number XD90154
Product Name 2,3,5-Triphenyl-2H-tetrazolium chloride
CAS 298-96-4
Molecular Formula C19H15N4·Cl
Molecular Weight 334.80
Storage Details 2 to 8 °C
Harmonized Tariff Code 29339980

 

Product Specification

Appearance Off-white/pale yellow crystalline powder
Assay Min. 98%
Melting Point 235 - 245 Deg C
Loss on Drying <3.0%
Water Content 0.5% Max
Residue on Ignition Max. 0.5%
Solubility in EtoH Pass
Solubility in Ethanol Clear and complete

 

 

To investigate the beneficial effect of the combination of butyrate, Lactobacillus casei, and L-carnitine in a rat colitis model.Rats were divided into seven groups. Four groups received oral butyrate, L-carnitine, Lactobacillus casei and the combination of three agents for 10 consecutive days. The remaining groups included negative and positive controls and a sham group. Macroscopic, histopathological examinations, and biomarkers such as tumor necrosis factor-alpha (TNF-α) and interlukin-1β (IL-1β), myeloperoxidase (MPO), thiobarbituric acid reactive substances (TBARS), and ferric reduced ability of plasma (FRAP) were determined in the colon.The combination therapy exhibited a significant beneficial effect in alleviation of colitis compared to controls. Overall changes in reduction of TNF-α (114.66 ± 18.26 vs 171.78 ± 9.48 pg/mg protein, P < 0.05), IL-1β (24.9 ± 1.07 vs 33.06 ± 2.16 pg/mg protein, P < 0.05), TBARS (0.2 ± 0.03 vs 0.49 ± 0.04 μg/mg protein, P < 0.01), MPO (15.32 ± 0.4 vs 27.24 ± 3.84 U/mg protein, P < 0.05), and elevation of FRAP (23.46 ± 1.2 vs 15.02 ± 2.37 μmol/L, P < 0.05) support the preference of the combination therapy in comparison to controls. Although the monotherapies were also effective in improvement of colitis markers, the combination therapy was much better in improvement of colon oxidative stress markers including FRAP, TBARS, and MPO.The present combination is a suitable mixture in control of experimental colitis and should be trialed in the clinical setting.


  • Previous:
  • Next:

  • Close

    2,3,5-Triphenyl-2H-tetrazolium chloride Cas:298-96-4 98% Off-white/pale yellow crystalline powder